Cargando…
300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period
BACKGROUND: An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease. The long-term consequences of COVID-19 are not fully understood and there is no clear consensus on the definition of post-acute sequelae of SARS-CoV-2 i...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644490/ http://dx.doi.org/10.1093/ofid/ofab466.502 |
_version_ | 1784610098160599040 |
---|---|
author | Dagher, Hiba Malek, Alexandre Chaftari, Anne-Marie Subbiah, Ishwaria M Jiang, Ying Lamie, Peter Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Borjan, Jovan Reyes, Cielito Flores, Mary Khawaja, Fareed Pande, Mala Ali, Norman Rojo, Raniv Karp, Daniel D Hachem, Ray Y Raad, Issam I |
author_facet | Dagher, Hiba Malek, Alexandre Chaftari, Anne-Marie Subbiah, Ishwaria M Jiang, Ying Lamie, Peter Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Borjan, Jovan Reyes, Cielito Flores, Mary Khawaja, Fareed Pande, Mala Ali, Norman Rojo, Raniv Karp, Daniel D Hachem, Ray Y Raad, Issam I |
author_sort | Dagher, Hiba |
collection | PubMed |
description | BACKGROUND: An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease. The long-term consequences of COVID-19 are not fully understood and there is no clear consensus on the definition of post-acute sequelae of SARS-CoV-2 infection (PASC). The reported prevalence of PASC widely varies from 10% up to 87%. The purpose of this study is to assess PASC in cancer patients following acute COVID-19 recovery. METHODS: We assessed cancer patients at MD Anderson Cancer Center who were diagnosed with COVID-19 disease between March 1, 2020 and Sept 1, 2020. Using patient questionnaires and medical chart reviews we followed these patients from March 2020 till May 2021. Patient questionnaires were sent out remotely daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. Chart reviews were conducted for each patient hospital re-admission and emergency department visit. These admissions were classified as either COVID-19 related or non-related. The persistence or emergence of new COVID19-related symptoms were captured at each COVID-19 related admission. RESULTS: We included 312 cancer patients with a median age of 57 years (18-86). The majority of patients had solid tumors (75%). Of the 312 patients, 188 (60%) reported long COVID-19 symptoms with a median duration of 7 months and up to 14 months after COVID-19 diagnosis. The most common symptoms reported included fatigue (82%), sleep disturbances (78%), myalgias (67%) and gastrointestinal symptoms (61%), followed by headache, altered smell or taste, dyspnea (47%) and cough (46%). A higher number of females reported a persistence of symptoms compared to males (63% vs 37%; p=0.036). Cancer type, neutropenia, lymphocytopenia, and hospital admission during acute COVID-19 disease were comparable in both groups and did not seem to contribute to a higher number of long-COVID-19 patients in our study group. CONCLUSION: Long-COVID occurs in 60% of cancer patients and may persist up to 14 months after acute illness. The most common symptoms are fatigue, sleep disturbance, myalgia and gastro-intestinal symptoms. DISCLOSURES: Fareed Khawaja, MBBS, Eurofins Viracor (Research Grant or Support) |
format | Online Article Text |
id | pubmed-8644490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86444902021-12-06 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period Dagher, Hiba Malek, Alexandre Chaftari, Anne-Marie Subbiah, Ishwaria M Jiang, Ying Lamie, Peter Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Borjan, Jovan Reyes, Cielito Flores, Mary Khawaja, Fareed Pande, Mala Ali, Norman Rojo, Raniv Karp, Daniel D Hachem, Ray Y Raad, Issam I Open Forum Infect Dis Poster Abstracts BACKGROUND: An increasing number of observational studies have reported the persistence of symptoms following recovery from acute COVID-19 disease. The long-term consequences of COVID-19 are not fully understood and there is no clear consensus on the definition of post-acute sequelae of SARS-CoV-2 infection (PASC). The reported prevalence of PASC widely varies from 10% up to 87%. The purpose of this study is to assess PASC in cancer patients following acute COVID-19 recovery. METHODS: We assessed cancer patients at MD Anderson Cancer Center who were diagnosed with COVID-19 disease between March 1, 2020 and Sept 1, 2020. Using patient questionnaires and medical chart reviews we followed these patients from March 2020 till May 2021. Patient questionnaires were sent out remotely daily for 14 days after COVID-19 diagnosis then weekly for 3 months, and then monthly thereafter. Chart reviews were conducted for each patient hospital re-admission and emergency department visit. These admissions were classified as either COVID-19 related or non-related. The persistence or emergence of new COVID19-related symptoms were captured at each COVID-19 related admission. RESULTS: We included 312 cancer patients with a median age of 57 years (18-86). The majority of patients had solid tumors (75%). Of the 312 patients, 188 (60%) reported long COVID-19 symptoms with a median duration of 7 months and up to 14 months after COVID-19 diagnosis. The most common symptoms reported included fatigue (82%), sleep disturbances (78%), myalgias (67%) and gastrointestinal symptoms (61%), followed by headache, altered smell or taste, dyspnea (47%) and cough (46%). A higher number of females reported a persistence of symptoms compared to males (63% vs 37%; p=0.036). Cancer type, neutropenia, lymphocytopenia, and hospital admission during acute COVID-19 disease were comparable in both groups and did not seem to contribute to a higher number of long-COVID-19 patients in our study group. CONCLUSION: Long-COVID occurs in 60% of cancer patients and may persist up to 14 months after acute illness. The most common symptoms are fatigue, sleep disturbance, myalgia and gastro-intestinal symptoms. DISCLOSURES: Fareed Khawaja, MBBS, Eurofins Viracor (Research Grant or Support) Oxford University Press 2021-12-04 /pmc/articles/PMC8644490/ http://dx.doi.org/10.1093/ofid/ofab466.502 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Abstracts Dagher, Hiba Malek, Alexandre Chaftari, Anne-Marie Subbiah, Ishwaria M Jiang, Ying Lamie, Peter Granwehr, Bruno John, Teny Guevara, Eduardo Yepez Borjan, Jovan Reyes, Cielito Flores, Mary Khawaja, Fareed Pande, Mala Ali, Norman Rojo, Raniv Karp, Daniel D Hachem, Ray Y Raad, Issam I 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period |
title | 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period |
title_full | 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period |
title_fullStr | 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period |
title_full_unstemmed | 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period |
title_short | 300. Long COVID in Cancer Patients: Preponderance of Symptoms in Majority of Patients Over Long Time Period |
title_sort | 300. long covid in cancer patients: preponderance of symptoms in majority of patients over long time period |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644490/ http://dx.doi.org/10.1093/ofid/ofab466.502 |
work_keys_str_mv | AT dagherhiba 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT malekalexandre 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT chaftariannemarie 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT subbiahishwariam 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT jiangying 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT lamiepeter 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT granwehrbruno 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT johnteny 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT guevaraeduardoyepez 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT borjanjovan 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT reyescielito 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT floresmary 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT khawajafareed 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT pandemala 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT alinorman 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT rojoraniv 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT karpdanield 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT hachemrayy 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod AT raadissami 300longcovidincancerpatientspreponderanceofsymptomsinmajorityofpatientsoverlongtimeperiod |